The Full Wiki

More info on Alfuzosin

Alfuzosin: Wikis

Advertisements
  
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Alfuzosin
Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Identifiers
CAS number 81403-80-7
ATC code G04CA01
PubChem 2092
DrugBank APRD00490
ChemSpider 2008
Chemical data
Formula C19H27N5O4 
Mol. mass 389.449 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 49%
Protein binding 82%-90%
Metabolism Hepatic (CYP3A4-mediated)
Half life 10 hours
Excretion Fecal (69%) and renal (24%)
Therapeutic considerations
Pregnancy cat. B2(AU) B(US)
Legal status POM (UK) -only (US)
Routes Oral
 Yes check.svgY(what is this?)  (verify)

Alfuzosin (INN, provided as the hydrochloride salt) is an α1 receptor antagonist used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xatral. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.


External links

Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message